DUBLIN–(BUSINESS WIRE)–The “Painful Diabetic Neuropathy Drugs Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 to 2030” report has been added to ResearchAndMarkets.com’s offering. The Painful Diabetic Neuropathy Drugs Market is forecasted to grow at a CAGR of 7% during the forecast period of 2022 to 2030. … [Read more…]
ReSound OMNIA is made for hearing in noisy environments with an outstanding 150% improvement in speech understanding Introducing enhanced ‘own voice’ perception, ReSound OMNIA hearing aids sound natural, feel natural and connect people to the world naturally BALLERUP, Denmark–(BUSINESS WIRE)–#HearingLoss–GN Hearing, the global leader in hearing aid innovation, today announces the launch of ReSound OMNIA … [Read more…]
– First new treatment regimen in more than 20 years to significantly improve outcomes in people with this fast-growing type of lymphoma – – Application is based on pivotal data from the Phase III POLARIX study showing Polivy plus R-CHP significantly reduced the risk of disease progression, relapse or death with comparable safety versus the … [Read more…]
– Gilead will Assume Responsibility for Clinical Development and Commercialization in Greater China and South Korea, among Other Asian Markets – FOSTER CITY, Calif.–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq: GILD) today announced an agreement with Everest Medicines to transfer all development and commercialization rights to Gilead for Trodelvy® (sacituzumab govitecan) in Greater China, South Korea, Singapore, … [Read more…]
Two joint ventures intend to produce 150,000 tons of lactic acid and 75,000 tons of polylactic acid annually to meet growing demand for plant-based solutions, including eco-friendly bioplastics Intended location for new production facilities will be Decatur, Illinois, U.S., with final investment decision to be made in 2023 SEOUL, South Korea & CHICAGO–(BUSINESS WIRE)–LG Chem … [Read more…]
LITTLE ELM, Texas–(BUSINESS WIRE)–Retractable Technologies, Inc. (NYSE American: RVP) reports that its operating income was $7.7 million for the first six months of 2022 and that it had an operating loss of $2.1 million for the second quarter of 2022, as compared to an operating income for the same periods last year of $36.1 million … [Read more…]
TORONTO–(BUSINESS WIRE)–Cybin Inc. (NEO:CYBN) (NYSE AMERICAN:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to TherapeuticsTM”, is pleased to announce the voting results for each of the matters presented at the Company’s annual meeting of shareholders held on August 15, 2022 (the “Meeting”). There were 71 shareholders represented in person or by … [Read more…]
Toragen is focused on uniquely selective drugs targeting cancers caused by the human papillomavirus (“HPV”) SAN DIEGO–(BUSINESS WIRE)–Toragen, Inc., a San Diego-based biotechnology company focused on developing, repurposing and commercializing uniquely selective drugs targeting cancers caused by the human papillomavirus (“HPV”), announced today the appointment of Mr. Paul Engler, of Amarillo, Texas, to the Board … [Read more…]
IRVING, Texas–(BUSINESS WIRE)–Biote today issued a correction to operating loss and net income for the three and six month periods ended June 30, 2022 in the press release titled “Biote Reports Second Quarter 2022 Financial Results,” issued on August 9, 2022. The other financial results reported in the original press release, revenue and adjusted EBITDA, … [Read more…]
Upfront $120 million tranche used to finance the full settlement of existing convertible notes held by Deerfield Management Company Deerfield Management Company to take equity as part of the settlement of existing convertible notes Owl Rock to make $6.25 million equity investment Seven-year term loan matures in 2029 and Company maintains cash runway into early … [Read more…]
